J
Jing Liu
Researcher at Janssen Pharmaceutica
Publications - 31
Citations - 475
Jing Liu is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Glycosyl acceptor & Fatty acid amide hydrolase. The author has an hindex of 11, co-authored 31 publications receiving 450 citations. Previous affiliations of Jing Liu include Johnson & Johnson & University of Illinois at Urbana–Champaign.
Papers
More filters
PatentDOI
Facile assembly of fused benzofuro-heterocycles
TL;DR: In this article, the synthesis of polycyclic structural components of pharmacological compounds, including fused benzofuro-heterocycles, through selective palladium-catalyzed cross-coupling and intramolecular cyclization, is described.
Journal ArticleDOI
C2-Amidoglycosylation. Scope and Mechanism of Nitrogen Transfer
Jing Liu,David Y. Gin +1 more
TL;DR: A one-pot C2-amidoglycosylation reaction for the synthesis of 2-N-acyl-2-deoxy-beta-pyranosides from glycals is described, allowing for the introduction of both natural and nonnatural amide functionalities at C2 with concomitant anomeric bond formation in a one-pots procedure.
Journal ArticleDOI
Acetamidoglycosylation with Glycal Donors: A One‐Pot Glycosidic Coupling with Direct Installation of the Natural C(2)‐N‐Acetylamino Functionality
TL;DR: A new method for direct C2-aza-glycosylation with glycal donors has been developed, employing the new reagent combination of thianthrene-S-oxide and trifluoroacetic anhydride for glycal activation, in an overall one-pot procedure.
Journal ArticleDOI
Preclinical Characterization of the FAAH Inhibitor JNJ-42165279.
John M. Keith,William M. Jones,Mark S. Tichenor,Jing Liu,Mark Seierstad,James A. Palmer,Michael Webb,Mark J. Karbarz,Brian Scott,Sandy J. Wilson,Lin Luo,Michelle L. Wennerholm,Leon Chang,Michele C. Rizzolio,Raymond Rynberg,Chaplan,Breitenbucher Jg +16 more
TL;DR: The pre-clinical characterization of the aryl piperazinyl urea inhibitor of fatty acid amide hydrolase (FAAH) JNJ-42165279 is described, which exhibited excellent ADME and pharmacodynamic properties as evidenced by its ability to block FAAH in the brain and periphery of rats.
Patent
2-aminopyrimidine modulators of the histamine h4 receptor
Hui Cai,Frank Chavez,James P. Edwards,Anne E. Fitzgerald,Jing Liu,Neelakandha S. Mani,Wiener Danielle,Michele C. Rizzolio,Brad M. Savall,Smith Deborah M,Jennifer D. Venable,Jianmei Wei,Ronald L. Wolin +12 more
TL;DR: In this article, 2-Aminopyrimidine compounds are described as H4 receptor modulators, which are used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4-RBP activity.